Associated tags: CD16, B-cell maturation antigen, BCMA, Downregulation and upregulation, NK, CD38, Immunotherapy, Multiple myeloma, Neoplasm, Survival, Daratumumab, Antibody, IPSC, ASH, CAR, Destiny, Therapy, Safety, Research, Cancer, Graft-versus-host disease, Patient, Vaccine, Janssen, Pharmaceutical industry, Food, Acute leukemia, Society, Tumor microenvironment
Locations: CAR
ASH,
Completeness,
Chronic lymphocytic leukemia,
Bone marrow,
Janssen,
GAAP,
Investigational New Drug,
Patient,
Investment,
Mab,
Autoimmune disease,
Graft-versus-host disease,
Multiple myeloma,
NK,
Research,
B-cell lymphoma,
FDA,
IND,
Ono Pharmaceutical,
Safety,
TRAC,
Neoplasm,
IPSC,
ADR,
Lymphoid leukemia,
HER2,
Cancer,
ONO,
CAR,
Destiny,
SAN,
B cell,
Therapy,
Escalation,
CXCR2,
Multi,
Regulation of tobacco by the U.S. Food and Drug Administration,
Tumor microenvironment,
Society,
Acute leukemia,
Food,
BCMA,
Vaccine,
Security (finance),
Pharmaceutical industry SAN DIEGO, May 03, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today reported business highlights and financial results for the first quarter ended March 31, 2023.
Key Points:
- Upon clearance of the current treatment cohorts, the Company plans to open and assess three-dose treatment cohorts starting at 1 billion cells per dose.
- Shares Outstanding: Common shares outstanding were 98.2 million, and preferred shares outstanding were 2.8 million, as of March 31, 2023.
- ET to review financial and operating results for the quarter ended March 31, 2023.
- The live webcast can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.fatetherapeutics.com.
Retrieved on:
Tuesday, February 28, 2023
Cancer,
IPSC,
IND,
Collaboration,
Chronic lymphocytic leukemia,
Multiple myeloma,
Safety,
Society,
Therapy,
Acute leukemia,
Investigational New Drug,
Workforce,
Mab,
Destiny,
Patient,
Completeness,
Tumor microenvironment,
HER2,
ADR,
D,
Food,
B cell,
TRAC,
Ono Pharmaceutical,
NK,
Research,
Investment,
Society for Immunotherapy of Cancer,
Graft-versus-host disease,
Exercise,
SITC,
B-cell lymphoma,
ONO,
CAR,
Annual general meeting,
Risk,
Immunotherapy,
FDA,
Regulation of food and dietary supplements by the U.S. Food and Drug Administration,
ASH,
BCMA,
CR,
CXCR2,
Cryptocurrency,
Vaccine,
Pharmaceutical industry,
Janssen Total Revenue: Revenue was $44.4 million for the fourth quarter of 2022, which was derived from the Company’s collaborations with Janssen and ONO.
Key Points:
- Total Revenue: Revenue was $44.4 million for the fourth quarter of 2022, which was derived from the Company’s collaborations with Janssen and ONO.
- R&D Expenses: Research and development expenses were $87.2 million for the fourth quarter of 2022, which includes $12.4 million of non-cash stock-based compensation expense.
- G&A Expenses: General and administrative expenses were $21.6 million for the fourth quarter of 2022, which includes $7.0 million of non-cash stock-based compensation expense.
- ET to review financial and operating results for the quarter and full year ended December 31, 2022.
Retrieved on:
Saturday, December 10, 2022
Johnson & Johnson,
Immunotherapy,
Canadian Aviation Regulations,
B-cell maturation antigen,
CD16,
BOR,
Administration,
Janssen,
NK,
CAR,
PD,
Cytokine release syndrome,
Security (finance),
SD,
Neoplasm,
Graft-versus-host disease,
Antibody,
AES,
Safety,
Cancer,
Maintenance,
Multiple myeloma,
NA,
Downregulation and upregulation,
CD38,
ASH,
ADCC,
IPSC,
Neutropenia,
CRS,
GPRC5D,
International Myeloma Foundation,
DLT,
Patient,
Survival,
Destiny,
SAE,
Research,
Patent,
Therapy,
Antigen,
Risk,
Death,
BCMA,
Daratumumab,
PR,
Janssen Pharmaceuticals,
Vaccine,
Pharmaceutical industry,
Fine chemical SAN DIEGO, Dec. 10, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today presented interim clinical data from the dose-escalation stage of its ongoing Phase 1 study of FT576 for patients with relapsed / refractory multiple myeloma (r/r MM) at the 64th American Society of Hematology Annual Meeting and Exposition. The off-the-shelf product candidate, which is derived from a clonal master engineered induced pluripotent stem cell (iPSC) line, incorporates a chimeric antigen receptor (CAR) targeting B-cell maturation antigen (BCMA) as well as a high-affinity, non-cleavable CD16 (hnCD16) Fc receptor to maximize antibody-dependent cellular cytotoxicity (ADCC) and enable dual-antigen targeting of myeloma cells through combination with monoclonal antibody (mAb) therapy. Preclinical data published last month in the journal Nature Communications (Cichocki et al. 2022, 13:7341) demonstrated that single-dose administration of FT576 was effective at controlling tumor growth in vivo, with deeper and more sustained anti-tumor activity observed through multi-dose administration of FT576 as well as in combination with the CD38-targeted monoclonal antibody daratumumab.
Key Points:
- Grade 3 or greater treatment-emergent AEs (TEAEs) not related to FT576 primarily included hematologic cytopenias associated with conditioning chemotherapy.
- Administration of three doses of FT555 as monotherapy further improved tumor clearance and showed superior activity compared to single-dose primary CAR T cells.
- Fate Therapeutics’ iPSC product platform is supported by an intellectual property portfolio of over 350 issued patents and 150 pending patent applications.
- Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer.
